Epirubicin hydrochloride and Breast cancer metastatic - a phase IV clinical study of FDA data

Summary:

Breast cancer metastatic is found among people who take Epirubicin hydrochloride, especially for people who are 60+ old, have been taking the drug for 1 - 6 months.

The phase IV clinical study analyzes which people take Epirubicin hydrochloride and have Breast cancer metastatic. It is created by eHealthMe based on reports of 3,214 people who have side effects when taking Epirubicin hydrochloride from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

With medical big data and AI algorithms, eHealthMe enables everyone to run phase IV clinical trial to detect adverse drug outcomes and monitor effectiveness. Our original studies have been referenced on 600+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Most recently, phase IV clinial trails for COVID 19 vaccines have been added, check here.



On Jun, 30, 2022

3,214 people reported to have side effects when taking Epirubicin hydrochloride.
Among them, 18 people (0.56%) have Breast cancer metastatic.


What is Epirubicin hydrochloride?

Epirubicin hydrochloride has active ingredients of epirubicin hydrochloride. eHealthMe is studying from 3,232 Epirubicin hydrochloride users for its effectiveness, alternative drugs and more.

What is Breast cancer metastatic?

Breast cancer metastatic is found to be associated with 840 drugs and 449 conditions by eHealthMe.

Number of Epirubicin hydrochloride and Breast cancer metastatic reports submitted per year:

Could Epirubicin hydrochloride cause Breast cancer metastatic?

Time on Epirubicin hydrochloride when people have Breast cancer metastatic *:

  • < 1 month: 0.0 %
  • 1 - 6 months: 66.67 %
  • 6 - 12 months: 33.33 %
  • 1 - 2 years: 0.0 %
  • 2 - 5 years: 0.0 %
  • 5 - 10 years: 0.0 %
  • 10+ years: 0.0 %

Age of people who have Breast cancer metastatic when taking Epirubicin hydrochloride *:

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 0.0 %
  • 40-49: 0.0 %
  • 50-59: 44.44 %
  • 60+: 55.56 %

Common drugs people take besides Epirubicin hydrochloride *:

  1. Afinitor: 5 people, 27.78%
  2. Xeloda: 3 people, 16.67%
  3. Taxotere: 3 people, 16.67%
  4. Taxol: 3 people, 16.67%
  5. Faslodex: 3 people, 16.67%
  6. Navelbine: 2 people, 11.11%
  7. Rivaroxaban: 1 person, 5.56%
  8. Paclitaxel: 1 person, 5.56%
  9. Magnesium: 1 person, 5.56%
  10. Fluorouracil: 1 person, 5.56%

Common side effects people have besides Breast cancer metastatic *:

  1. Malignant Neoplasm Progression (cancer tumour came back): 9 people, 50.00%
  2. Disease Progression: 7 people, 38.89%
  3. Metastases To Liver (cancer spreads to liver): 5 people, 27.78%
  4. Metastases To Bone (cancer spreads to bone): 4 people, 22.22%
  5. Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection): 3 people, 16.67%
  6. Cough: 2 people, 11.11%
  7. Lymphangiosis Carcinomatosa (inflammation of the lymph vessels can lead to cancer): 2 people, 11.11%
  8. Metastases To Lung (cancer spreads to lung): 2 people, 11.11%
  9. Metastases To Lymph Nodes (cancer spreads to lymph node): 2 people, 11.11%
  10. Metastases To The Mediastinum (cancer spreads to mediastinum): 2 people, 11.11%

Common conditions people have *:

  1. Breast Cancer: 6 people, 33.33%
  2. Metastases To Bone (cancer spreads to bone): 3 people, 16.67%
  3. Metastases To Lung (cancer spreads to lung): 1 person, 5.56%
  4. Metastases To Liver (cancer spreads to liver): 1 person, 5.56%
  5. Breast Cancer Stage Ii: 1 person, 5.56%
  6. Breast Cancer Female: 1 person, 5.56%
  7. Adverse Event: 1 person, 5.56%

* Approximation only. Some reports may have incomplete information.

Do you take Epirubicin hydrochloride and have Breast cancer metastatic?

Check whether Breast cancer metastatic is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.



Related studies

Alternative drugs to, pros and cons of Epirubicin hydrochloride:

Breast cancer metastatic treatments and more:

COVID vaccines that are related to Breast cancer metastatic:

How severe was Breast cancer metastatic and when was it recovered:

Expand to all the drugs that have ingredients of epirubicin hydrochloride:

Common drugs associated with Breast cancer metastatic:

All the drugs that are associated with Breast cancer metastatic:

Common conditions associated with Breast cancer metastatic:

All the conditions that are associated with Breast cancer metastatic:

How the study uses the data?

The study uses data from the FDA. It is based on epirubicin hydrochloride (the active ingredients of Epirubicin hydrochloride) and Epirubicin hydrochloride (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: